01 How it works
It simply combines the two. BPC-157 is thought to bring blood supply and repair cells to a specific injury; TB-500 supports cell migration and tissue regeneration more broadly. Together they are used when an injury is stubborn or when recovery from heavy training is lagging.
02 Common uses
03 Run profile
One draw covers both compounds. Start low, step up in phases, once a day with weekends off. Most runs last six to twelve weeks.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
04 Pairs well with
05 What to watch for
The same as its two parts: mild injection-site irritation is the main thing, occasionally headache or sluggishness from the TB-500. Rotate sites. Anyone with a personal or family history of cancer should talk to a doctor first.
06 Evidence & status
Not approvedNo trials exist on the blend itself; the evidence is that of its two components — mostly animal research and real-world use.
Not FDA-approved (both components are unapproved). The October 2026 HHS enforcement policy covers single-ingredient products only, so a combined vial falls outside it.
Sources
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS Journal, 2025 · Review
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healingCell and Tissue Research, 2019 · Review
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applicationsExpert Opinion on Biological Therapy, 2012 · Review
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitroJournal of Chromatography B, 2024 · Reference
- HHS Draft Policy Eases Enforcement on 6 Compounded PeptidesThe American Journal of Managed Care (AJMC), 2026 · Regulator document
- The Prohibited ListWorld Anti-Doping Agency, 2026 · Regulator document
Status and sources last checked November 3, 2026. Something out of date? Tell us.
07 How long until it works
The blend has one exploratory animal study and no human data, so the timescale is that of its parts: animal tendon and tissue repair measures changing over two to four weeks, and real-world reports on a similar horizon. That is why the run profile is a six-to-twelve-week block, the same as BPC-157 alone. If a stubborn injury is no better after eight weeks, that is a reason to see a sports medicine doctor rather than extend the run.
08 The blend vs two separate vials
The blend is convenience: one draw, one injection, a fixed ratio. Two vials give control: BPC-157 can go near the injury and TB-500 elsewhere, and each can be stepped up on its own. Since neither component has a human trial, there is no evidence that either arrangement works better; people choose on convenience and on whether they want to adjust the two separately.
There is one regulatory difference worth knowing: the October 2026 HHS compounding policy covers single-ingredient products only, so a pharmacy can supply BPC-157 and TB-500 as separate vials under it, but not the combined vial.
The BPC-157 dossier →09 Stacking
It is already a stack. KPV is the common addition when inflammation is part of the picture. No study has tested any of these combinations in people.
10 Where it stands legally
Neither component is approved anywhere. Both were recommended for the 503A compounding list by the FDA’s advisory committee in July 2026 (non-binding), and both are covered, as single ingredients, by the October 2026 HHS enforcement-discretion policy; the combined vial is not.
In sport the blend is banned twice over: TB-500 is named on WADA’s Prohibited List under S2, and BPC-157 falls under S0.
11 FAQ
Why a blend instead of two vials?
Convenience — one draw, one schedule. The trade-off is you cannot adjust the two separately.
On the pen, how much of each do I get?
Each dial step delivers equal amounts of both. Ask for the exact numbers for your cartridge.
Is it stronger than BPC-157 alone?
It covers more ground rather than being “stronger” — local plus systemic repair.
Is the Wolverine Stack banned in sport?
Yes. TB-500 is named on WADA’s list under S2 and BPC-157 falls under S0; the blend is prohibited at all times.
Can a pharmacy compound the Wolverine Stack?
Not under the October 2026 HHS policy, which covers single-ingredient products only. Separate BPC-157 and TB-500 vials are covered; the blend is not.
Is there any study of the two together?
One exploratory animal study of the combination, and no human data. The evidence on this page is for the components separately.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.